GLP-1 News — Week of September 21, 2026
The GLP-1 stories that mattered this week — what happened, and what each one means for you if you're using or considering these medications. Every story links to its primary source, and nothing here is influenced by advertisers.
Novo's CagriSema delivers greater weight loss than tirzepatide in phase 3 REIMAGINE 5 trial
Novo Nordisk reported topline phase 3 results showing that once-weekly CagriSema, a combination of cagrilintide (an amylin analog) and semaglutide, led to more weight loss than tirzepatide in adults with obesity in the REIMAGINE 5 trial. The company also highlighted strong glucose-lowering results in people with type 2 diabetes from the REDEFINE 9 trial, and noted that CagriSema is already under FDA review for chronic weight management. (2026-09-21)
What this means for you: You cannot get CagriSema yet, but this makes it more likely that in a few years there could be an injectable that offers even more weight loss than today’s GLP-1 and GLP-1/GIP drugs. If you are deciding on Wegovy or Zepbound now, these findings are future-facing rather than a reason to delay starting an approved option.
Source: Novo Nordisk
Related on Metabolic Ledger: /drugs/cagrisema
Novo previews real-world data for oral Wegovy-style pill and next-gen obesity drugs ahead of EASD 2026
Novo Nordisk announced that it will present new data at the European Association for the Study of Diabetes 2026 meeting, including real-world evidence from the OCTANE study of an obesity-dose oral semaglutide pill in adults with overweight or obesity. The company will also highlight pipeline updates, including next-generation amylin-based obesity therapies that build on its current GLP-1 portfolio. (2026-09-16)
What this means for you: If you prefer pills over injections, this is a sign that an obesity-dose Wegovy pill is moving forward, but it is not yet FDA-approved for weight loss in the United States. For now, if you want GLP-1-based weight loss treatment, you still need to use injectable options while keeping an eye on how these oral data look and whether regulators approve them.
Source: Novo Nordisk
Related on Metabolic Ledger: /drugs/rybelsus-vs-wegovy
Novo Nordisk’s Capital Markets Day underscores long-term bet on obesity drugs including CagriSema and oral semaglutide
At its 2026 Capital Markets Day, Novo Nordisk highlighted obesity and cardiometabolic disease as core growth drivers, singling out CagriSema and oral Wegovy-style therapies as major future products. The company framed heavy investment in follow-on and combination drugs as key to managing upcoming patent expirations and sustaining long-term growth in obesity care. (2026-09-21)
What this means for you: This does not immediately change prices or insurance coverage, but it signals that Novo plans to stay deeply committed to obesity drugs rather than pulling back. Over time, that makes it more likely you will see expanding treatment options and manufacturing capacity, though you should still expect near-term access to be shaped mainly by your insurer’s policies and existing supply limits.
Source: Novo Nordisk
Related on Metabolic Ledger: /regulatory/glp1-off-label-uses
FDA safety context: GLP-1 drugs remain under active review for GI and mental health risks
Existing FDA communications from early 2026 outline ongoing safety review of GLP-1 receptor agonists, including potential links to suicidal thoughts and serious gastrointestinal problems like ileus or intestinal obstruction. Some of these risks are now reflected in product labels for semaglutide and tirzepatide, but regulators have not concluded that GLP-1 drugs cause suicidal behavior and have not issued new safety warnings in the week of September 18–25, 2026. (2026-01-13)
What this means for you: Nothing about GLP-1 safety labeling changed this week, but you should still be alert to severe or persistent stomach pain, vomiting, constipation, or mood changes and report them quickly. If you are starting or staying on a GLP-1, the current evidence supports use when benefits outweigh risks, with the understanding that the FDA is continuing to monitor safety closely.
Source: FDA
Related on Metabolic Ledger: /regulatory/glp1-long-term-safety